These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8622092)

  • 1. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group.
    Bruera E; Sloan P; Mount B; Scott J; Suarez-Almazor M
    J Clin Oncol; 1996 May; 14(5):1713-7. PubMed ID: 8622092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain.
    Hays H; Hagen N; Thirlwell M; Dhaliwal H; Babul N; Harsanyi Z; Darke AC
    Cancer; 1994 Sep; 74(6):1808-16. PubMed ID: 7521784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
    Hagen NA; Babul N
    Cancer; 1997 Apr; 79(7):1428-37. PubMed ID: 9083166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
    Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ
    J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain.
    Watanabe S; Pereira J; Tarumi Y; Hanson J; Bruera E
    J Palliat Med; 2008 May; 11(4):570-4. PubMed ID: 18454609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain.
    Bruera E; Belzile M; Pituskin E; Fainsinger R; Darke A; Harsanyi Z; Babul N; Ford I
    J Clin Oncol; 1998 Oct; 16(10):3222-9. PubMed ID: 9779695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
    Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
    J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a new once daily hydromorphone formulation in comparison with twice daily administration in chronic pain: a randomized, double-blind, cross-over study.
    Nold GE; Maritz MA; Schwittay A; Schumann C; Rey H
    Curr Med Res Opin; 2016 May; 32(5):869-77. PubMed ID: 26824884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study.
    Song EK; Shim H; Han HS; Sun D; Lee SI; Kang MH; Lee K; Cho D; Cho IS; Park SY; Kim S; Yim CY
    Pain Res Manag; 2015; 20(6):293-9. PubMed ID: 26474382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.
    Beaulieu AD; Peloso P; Bensen W; Clark AJ; Watson CP; Gardner-Nix J; Thomson G; Piraino PS; Eisenhoffer J; Harsanyi Z; Darke AC
    Clin Ther; 2007 Jan; 29(1):49-60. PubMed ID: 17379046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydromorphone extended release for neuropathic and non-neuropathic/nociceptive chronic low back pain: a post hoc analysis of data from a randomized, multicenter, double-blind, placebo-controlled clinical trial.
    Nalamachu S; Hale M; Khan A
    J Opioid Manag; 2014; 10(5):311-22. PubMed ID: 25350473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of morning vs. evening dosing of extended-release hydromorphone on sleep physiology in patients with low back pain: a pilot study.
    Webster LR; Smith MD; Mackin S; Iverson M
    Pain Med; 2015 Mar; 16(3):460-71. PubMed ID: 25279807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study].
    Junker U; Figge V
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():91-6. PubMed ID: 16261943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pre-emptive hydromorphone administration on postoperative pain relief--a randomized controlled trial.
    Kopp A; Wachauer D; Hoerauf KH; Zulus E; Reiter WJ; Steltzer H
    Wien Klin Wochenschr; 2000 Dec; 112(23):1002-6. PubMed ID: 11190708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose equivalence of immediate-release hydromorphone and once-daily osmotic-controlled extended-release hydromorphone: a randomized, double-blind trial incorporating a measure of assay sensitivity.
    Cruciani RA; Katz N; Portenoy RK
    J Pain; 2012 Apr; 13(4):379-89. PubMed ID: 22424912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
    Rauck R; Rapoport R; Thipphawong J
    Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
    Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
    Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
    Clemens KE; Klaschik E
    Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.